Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV) Business Wire Sep 26, 2024 10:00am
Enanta Pharmaceuticals to Participate in Investor Conferences in September Business Wire Sep 3, 2024 11:00am
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Business Wire Aug 5, 2024 8:01pm